Cancer and Metastasis Reviews

Papers
(The TQCC of Cancer and Metastasis Reviews is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities351
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer213
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms202
Obesity and cancer140
Clonal tracking in cancer and metastasis132
Regulation of dormancy during tumor dissemination: the role of the ECM113
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression103
The functions and modifications of tRNA-derived small RNAs in cancer biology91
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions84
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer68
Targeting lipid metabolism in cancer: neuroblastoma67
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?67
CAR T-cell therapy to treat multiple myeloma: current state and future directions61
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?59
p73 isoforms meet evolution of metastasis58
Cell-cell interactions mediating primary and metastatic breast cancer dormancy55
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review53
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond47
Biography—Mathieu Boissan, Pharm.D., Ph.D45
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives45
Preface42
Neuropeptide Y in cancer—biological functions and potential clinical implications40
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer40
Biographies38
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance38
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications36
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance36
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy35
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy35
The role of cancer cell bioenergetics in dormancy and drug resistance35
Clusterin: a marker and mediator of chemoresistance in colorectal cancer35
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis35
Short-chain fatty acids in cancer pathogenesis35
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development34
Tumor necrosis factor superfamily signaling: life and death in cancer34
Carcinoma of unknown primary (CUP): an update for histopathologists33
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions33
Clinical interventions to break the obesity and cancer link: a narrative review33
Vaping and tumor metastasis: current insights and progress33
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy30
Functional and clinical roles of stromal PDGF receptors in tumor biology30
Kenneth V. Honn, Ph.D. (1946–2023)29
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution29
The emerging roles of histone demethylases in cancers29
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy28
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape28
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective27
OX40/OX40 ligand and its role in precision immune oncology27
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies26
Ferroptosis: iron release mechanisms in the bioenergetic process25
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect25
HOXA9 transcription factor is a double-edged sword: from development to cancer progression24
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases24
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting24
Biographies23
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics23
Is cancer an intelligent species?23
New progress of tuberculosis scar carcinoma23
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs23
0.19329214096069